On July 17, 2026, JPMorgan Chase & Co. bought 566,578 H shares of TIGERMED at an average of HKD 36.8414 per share, involving about HKD 20.87 million.
Prior to the acquisition, JPMorgan Chase & Co.'s long position in TIGERMED was 20.77 million shares, representing 16.86%; following the acquisition, the holding changed to 21.34 million shares, with the long position ratio rising to 17.32%.